

GATEWAY HEALTH PLAN®

PHARMACY AND THERAPEUTICS COMMITTEE MEETING

DATE: March 11, 2009

TIME: 5:00PM

The attached minutes of the March 11, 2009 meeting of the Pharmacy and Therapeutics

("P & T") Committee have participants' names redacted.

No actions taken by the P & T Committee constitute formulary changes unless and until approved by the Department of Public Welfare.

GATEWAY HEALTH PLAN®
PHARMACY AND THERAPEUTICS COMMITTEE MEETING

DATE: March 11, 2009
TIME: 5:00PM

PRESENT:

Dennis Andrew Sebastian RPh, MS

[REDACTED], R.Ph.
[REDACTED], PharmD
[REDACTED], RPh.
[REDACTED], PharmD
[REDACTED], MD
[REDACTED], MD
[REDACTED], MD
[REDACTED], PharmD
[REDACTED], MD
[REDACTED], MD
[REDACTED], MD
[REDACTED], MD

Pharmacy Director, Gateway
Clinical Pharmacist, Gateway
Clinical Pharmacist, Gateway
Manager, Clinical Pharmacy, Gateway
Clinical Pharmacist, Gateway
Medical Director, Gateway
Medical Director, Gateway
Medical Director, Gateway
Highmark BC/BS
Family Practitioner, Butler County
Pediatrician, Allegheny County
Internal Medicine, Allegheny County
Internal Medicine, Allegheny County
Community Care Behavioral Health

Guests:

[REDACTED]
[REDACTED]

Pharmacy Student, Duquesne University
Pharmacy Student, University of Pittsburgh

CALL TO ORDER

Having confirmed quorum, Mr. Sebastian called the meeting to order at 5:10 p.m.

I. REVIEW OF MINUTES

Discussion: The Committee reviewed the minutes from the December 10, 2008 P&T Committee meeting.

Action: With no further comments, the minutes from the December 10, 2008 meeting were unanimously approved.

II. OLD BUSINESS

P&T Changes

The P&T Committee will experience two DPW directed changes: 1) Gateway will post the minutes on its website beginning with the March 2009 meeting and 2) Gateway will place one behavioral health and physical health member advocate on the Committee. Gateway is currently recruiting a retail pharmacist to serve as the physical health advocate. Gateway will recruit an existing P&T physician to serve as the behavioral health advocate.

Darvocet

The Committee reviewed the meeting materials pertaining to Darvocet. A short discussion spoke to the events at the two previous P&T Committee meetings leading to tonight's meeting and the request for removal of Darvocet.

Action Taken: With no further comments, the Committee voted Darvocet to be removed from the Medicaid formulary (12 for; 1 abstained from voting).

III. NEW BUSINESS – FORMULARY REVIEW (New Products)

Milnacipran (Savella, Forest)

Discussion: The Committee discussed the clinical details of Savella.

Action Taken: With no further comments, the Committee voted Savella as a "may add" (7for; 6 against; 1 abstained from voting).

Febuxostat (Uloric, Takeda)

Discussion: The Committee discussed the clinical details of Uloric.

Action Taken: With no further comments, the Committee unanimously voted Uloric as a "do not add."

IV. ABBREVIATED REVIEWS:

Fenofibric acid (Trilipix, Abbott Labs)

Discussion: The Committee discussed the clinical details of Trilipix.

Action taken: With no further comments, the Committee unanimously gave Trilipix "do not add" status.

Zolpidem oral spray (Zolpimist, NovaDel Pharma)

Discussion: The Committee discussed the clinical details of Zolpimist.

Action taken: With no further comments, the Committee unanimously gave Zolpimist “do not add” status.

Oxybutynin gel 10% (Gelnique, Watson)

Discussion: The Committee discussed the clinical details of Gelnique.

Action taken: With no further comments, the Committee unanimously gave Gelnique “do not add” status.

Adapalene 0.1%/benzoyl peroxide 2.5% (Epiduo, Galderma)

Discussion: The Committee discussed the clinical details of Epiduo.

Action taken: With no further comments, the Committee unanimously gave Epiduo “do not add” status.

Dexlansoprazole (Kapidex, Takeda)

Discussion: The Committee discussed the clinical details of Kapidex.

Action taken: With no further comments, the Committee gave Kapidex “do not add” status (12 for; 1 abstained from voting).

Calcitriol ointment (Vectical, Galderma)

Discussion: The Committee discussed the clinical details of Vectical.

Action taken: With no further comments, the Committee unanimously gave Vectical “do not add” status.

Dapsone gel (Aczone, Allergan)

Discussion: The Committee discussed the clinical details of Aczone.

Action taken: With no further comments, the Committee gave Aczone “do not add” status (12 for; 1 abstained from voting).

V. NEW FDA INDICATIONS

Reclast

New Indication: On December 19, 2008 the FDA approved the use of Reclast as a treatment to increase bone mass in men with osteoporosis.

Previous Status: Nonformulary

Voted Status: No change in status

Pegintron

New Indication: On December 11, 2008, the FDA approved the use of Pegintron as combination therapy with Rebetol in chronic hepatitis C patients ≥ 3 years with compensated liver disease previously untreated with interferon alpha.

Previous Status: Formulary

Voted Status: N/A

VI. CLASS REVIEWS

Anti-Infectives:

Discussion: The Committee reviewed and discussed the existing anti-infective class as published in the Gateway Medicaid Formulary.

Action taken: With no further comments on the class, the Committee unanimously approved the anti-infective class as currently published on the Gateway Medicaid Formulary.

Cancer/immunosuppression:

Discussion: The Committee reviewed and discussed the existing cancer/immunosuppression class as published in the Gateway Medicaid Formulary.

Action taken: With no comments, the Committee unanimously approved the respiratory class currently published on the Gateway Medicaid Formulary.

Cardiovascular:

Discussion: The Committee reviewed and discussed the existing cardiovascular class as published in the Gateway Medicaid Formulary.

Action taken: With no comments, the Committee unanimously approved the cardiovascular class currently published on the Gateway Medicaid Formulary.

VII. NEW POLICY REVIEWS

Humira Medicaid Prior Authorization

Discussion: The Committee reviewed the specialty comments from rheumatology and discussed the proposed Humira Medicaid prior authorization policy

Action taken: The Committee unanimously approved the Humira prior authorization policy as presented in the meeting materials.

Synvisc Medicaid Prior Authorization

Discussion: The Committee reviewed the specialty comments from orthopedic surgery concerning the proposed Synvisc Medicaid prior authorization policy.

Action taken: The Committee unanimously approved the Synvisc prior authorization policy as presented in the meeting materials.

Galantamine HBr Medicaid Prior Authorization

Discussion: The Committee reviewed the proposed galantamine HBr Medicaid prior authorization policy. The proposed policy is very similar to the existing prior authorization policies currently in effect for both Aricept and Exelon.

Action taken: The Committee unanimously approved the galantamine HBr prior authorization policy as presented in the meeting materials.

VIII. 4Q08 CDUR REPORTS

Medicaid

Drug-Drug Interaction Summary Report 4Q08

The meeting materials contained the details of the drug-drug interaction summary report.

Action taken: With no further comments, the Committee approved the report as stated in the meeting materials.

Duplicate Therapy Summary Report 4Q08

The meeting materials contained the details of the duplicate therapy summary report.

Action taken: With no further comments, the Committee approved the report as stated in the meeting materials.

Min/Max Report 4Q08

The meeting materials contained the details of the min/max report. There were few changes from 2008. The low dose atypical step edit may impact this report moving forward in 2009.

Action taken: With no further comments, the Committee approved the report as stated in the meeting materials.

IX. MISCELLANEOUS

Tracleer deletion/Letairis addition

Discussion: The Committee reviewed the meeting materials and the specialty comments from pulmonology concerning the proposed Tracleer formulary removal and Letairis addition. Gateway will grandfather existing users of Tracleer.

Action taken: The Committee unanimously approved the proposed deletion and addition as presented.

Aranesp formulary removal

Discussion: The Committee discussed the request to remove Aranesp from the Medicaid formulary.

Action taken: The Committee unanimously approved the proposed Aranesp deletion.

Generic Pipeline

The Committee reviewed the generic pipeline as distributed in the meeting materials as an informational item.


CNS


The Committee reviewed and discussed the progress of the CNS initiative thus far as an informational item.

X. ADJOURNMENT

The next Committee meeting is on Wednesday June 10, 2009. There being no further business, the Committee adjourned at 6:40 p.m.

Respectfully Submitted
Dennis A. Sebastian, RPh, MS
Director Pharmacy Services
Gateway Health Plan®

 Date: 6-10-09

Completed by:

Clinical Pharmacist
Gateway Health Plan®

 Date: 6-10-09